FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average I	burden							

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LANGER ROBERT					IN	2. Issuer Name and Ticker or Trading Symbol INVIVO THERAPEUTICS HOLDINGS CORP. [NVIV]										ip of Reportin plicable) ctor	g Perso	n(s) to Is		
(Last) (First) (Middle) 98 MONTVALE ROAD						3. Date of Earliest Transaction (Month/Day/Year) 06/29/2012										er (give title w)	Other below		(specify	
(Street) NEWTO	IEWTON MA 02459						4. If Amendment, Date of Original Filed (Month/Day/Year)									aal or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deriv	ative	Sec	uritie	s Acc	quired	, Dis	sposed o	f, or	Bene	ficially	/ Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4				Secui Benet Owne	5. Amount of Securities Beneficially Owned Following		ership Direct ndirect r. 4)	7. Nature of Indirect Beneficial Ownership			
						Code	v	Amount	(A) (D)	or P	ice	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)				
COMMON STOCK, \$0.00001 PAR VALUE 06/29/2					2012	012		S		24,780	I	\$	2.307(1	7,	7,717,333)			
COMMON STOCK, \$0.00001 PAR VALUE 07/02.					2012				S		20,220	I	\$	\$2.387(2)		7,697,113)		
		Ta	able II -								osed of, onvertib				wned		,			
1. Title of Derivative Security (Instr. 3)	ivative conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)			4. Transa Code (8)	nstr.	5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (In	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dire or I (I) (nership m: ect (D) ndirect Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.30 to \$2.32, inclusive. The reporting person undertakes to provide InVivo Therapeutics Holdings Corp. ("InVivo"), any security holder of InVivo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 and footnote 2.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.36 to \$2.42, inclusive.

/S/ ELIZABETH FRASER, ATTORNEY-IN-FACT 07/02/2012

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.